← Leaderboards
Stuart Sheldon Winter
University Of New Mexico
$428,969
Attributed
$633,218
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $224.7K · FY2009–24$250K$187.5K$125K$62.5K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$633,218 · 2
By mechanism
R21$408,498 · 1
R01$224,720 · 1
Top collaborators
- Peter M Gordon2 shared
Most similar at University Of New Mexico
Same institution · by research overlap
- Richard S Larson$48,778,223
- Scott A. Ness$11,732,063
- Cheryl L Willman$57,213,396
Others in their field
Top investigators on “Pharmacologic Substance”
- David Heimbrook · Leidos Biomedical Research, Inc.$127,683,054
- Myron S Cohen · Family Health International$104,232,876
- Wafaa M. El-Sadr · Columbia University Health Sciences$104,068,526
- Garret A Fitzgerald · University Of Pennsylvania$73,814,804
- James Dennis Neaton · Northwestern University$65,107,995
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$53,206,876
Research focus
Pharmacologic SubstanceCell SurfaceLeukemic CellResponseCell SurvivalCellsCell Surface ReceptorsLeukemiaReceptorSamplingPathway InteractionsGeneticAntibodiesAdolescentCancer PatientAlgorithmsB-LymphocytesBurden Of IllnessCancer TherapyB Cell TherapyB Cell RepertoireAdverse EventAcute Lymphocytic LeukemiaB-Cell Lymphomas
Grant awards (3)
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma$189,780
R21 · FY2024 · CA · contact PI
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma$218,718
R21 · FY2023 · CA · contact PI
Microenvironmental mechanisms of leukemia cell survival$224,720
R01 · FY2009 · CA · contact PI